Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Scilex Holding Co. (SCLX)

Scilex Holding Co. (SCLX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.2360 +0.0080 (+3.51%) 02/28/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.2250 -0.0110 (-4.66%) 18:59 ET
Quote Overview for Fri, Feb 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.2106
Day High
0.2390
Open 0.2290
Previous Close 0.2280 0.2280
Volume 1,883,800 1,883,800
Avg Vol 1,338,610 1,338,610
Stochastic %K 9.15% 9.15%
Weighted Alpha -85.41 -85.41
5-Day Change -0.0938 (-28.44%) -0.0938 (-28.44%)
52-Week Range 0.2100 - 2.6300 0.2100 - 2.6300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,422
  • Shares Outstanding, K 243,313
  • Annual Sales, $ 46,740 K
  • Annual Income, $ -114,330 K
  • EBIT $ -69 M
  • EBITDA $ -65 M
  • 60-Month Beta 1.06
  • Price/Sales 0.48
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.87
  • Most Recent Earnings $-0.18 on 01/17/25
  • Next Earnings Date 03/10/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 300.75% ( -28.51%)
  • Historical Volatility 77.18%
  • IV Percentile 90%
  • IV Rank 41.54%
  • IV High 701.38% on 01/03/25
  • IV Low 16.01% on 03/13/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 66
  • Volume Avg (30-Day) 177
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 6,307
  • Open Int (30-Day) 7,213

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.12
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +64.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2100 +12.38%
on 02/27/25
Period Open: 0.4471
0.4550 -48.13%
on 01/29/25
-0.2111 (-47.22%)
since 01/28/25
3-Month
0.2100 +12.38%
on 02/27/25
Period Open: 0.6149
0.7450 -68.32%
on 12/02/24
-0.3789 (-61.62%)
since 11/27/24
52-Week
0.2100 +12.38%
on 02/27/25
Period Open: 2.4200
2.6300 -91.03%
on 02/29/24
-2.1840 (-90.25%)
since 02/28/24

Most Recent Stories

More News
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

SCLX : 0.2360 (+3.51%)
Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication

SCLX : 0.2360 (+3.51%)
Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

SCLX : 0.2360 (+3.51%)
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

SCLX : 0.2360 (+3.51%)
Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

SCLX : 0.2360 (+3.51%)
Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication

SCLX : 0.2360 (+3.51%)
Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

SCLX : 0.2360 (+3.51%)
Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

SCLX : 0.2360 (+3.51%)
Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch

SCLX : 0.2360 (+3.51%)
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7,...

SCLX : 0.2360 (+3.51%)

Business Summary

Scilex Holding Company is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Scilex Holding Company, formerly known as Vickers Vantage Corp. I, is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 0.2749
2nd Resistance Point 0.2569
1st Resistance Point 0.2465
Last Price 0.2360
1st Support Level 0.2181
2nd Support Level 0.2001
3rd Support Level 0.1897

See More

52-Week High 2.6300
Fibonacci 61.8% 1.7056
Fibonacci 50% 1.4200
Fibonacci 38.2% 1.1344
Last Price 0.2360
52-Week Low 0.2100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements